The reality of using primaquine
Open Access
- 27 December 2010
- journal article
- case report
- Published by Springer Nature in Malaria Journal
- Vol. 9 (1) , 376
Abstract
Primaquine is currently the only medication used for radical cure of Plasmodium vivax infection. Unfortunately, its use is not without risk. Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency have an increased susceptibility to haemolysis when given primaquine. This potentially fatal clinical syndrome can be avoided if patients are tested for G6PD deficiency and adequately informed before being treated.Keywords
This publication has 28 references indexed in Scilit:
- Clinical aspects of hemolysis in patients with P. vivax malaria treated with primaquine, in the Brazilian AmazonThe Brazilian Journal of Infectious Diseases, 2010
- Positively Selected G6PD -Mahidol Mutation Reduces Plasmodium vivax Density in Southeast AsiansScience, 2009
- The pathophysiology of vivax malariaTrends in Parasitology, 2009
- A Randomised Trial of an Eight-Week, Once Weekly Primaquine Regimen to Prevent Relapse of Plasmodium vivax in Northwest Frontier Province, PakistanPLOS ONE, 2008
- G6PD deficiency: the genotype-phenotype associationBlood Reviews, 2007
- Use of pictorial aids in medication instructions: A review of the literatureAmerican Journal of Health-System Pharmacy, 2006
- Can primaquine therapy for vivax malaria be improved?Trends in Parasitology, 2003
- Screening for glucose‐6‐phosphate dehydrogenase deficiency using a modified formazan method: A pilot study on Filipino male newbornsPediatrics International, 2003
- Nosocomial bacteremia due to Acinetobacter baumannii: epidemiology, clinical features and treatmentClinical Microbiology and Infection, 2002
- Teaching Patients with Low Literacy SkillsAJN, American Journal of Nursing, 1996